Cara Therapeutics, Inc. Expected to Post FY2028 Earnings of ($0.21) Per Share (NASDAQ:CARA)

Cara Therapeutics, Inc. (NASDAQ:CARA) – Investment analysts at HC Wainwright issued their FY2028 earnings estimates for Cara Therapeutics in a research report issued on Friday, April 12th. HC Wainwright analyst O. Livnat expects that the biopharmaceutical company will earn ($0.21) per share for the year. HC Wainwright currently has a “Buy” rating and a $2.50 target price on the stock. The consensus estimate for Cara Therapeutics’ current full-year earnings is ($1.25) per share.

Other equities research analysts have also recently issued research reports about the stock. Canaccord Genuity Group cut their price target on shares of Cara Therapeutics from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, March 6th. Needham & Company LLC restated a “buy” rating and set a $5.00 price objective on shares of Cara Therapeutics in a research report on Wednesday, April 10th. Finally, StockNews.com downgraded shares of Cara Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, March 6th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, Cara Therapeutics presently has an average rating of “Hold” and an average price target of $9.75.

Cara Therapeutics Stock Down 5.7 %

NASDAQ:CARA opened at $0.76 on Monday. The company’s 50 day moving average price is $0.81 and its 200-day moving average price is $0.93. Cara Therapeutics has a 52 week low of $0.50 and a 52 week high of $4.67. The stock has a market cap of $41.76 million, a price-to-earnings ratio of -0.35 and a beta of 0.70.

Cara Therapeutics (NASDAQ:CARA) last posted its quarterly earnings results on Monday, March 4th. The biopharmaceutical company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.02). Cara Therapeutics had a negative net margin of 565.21% and a negative return on equity of 122.10%. The firm had revenue of $3.00 million for the quarter, compared to analysts’ expectations of $2.34 million. During the same quarter in the previous year, the company earned ($0.56) EPS.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in CARA. Envestnet Asset Management Inc. bought a new position in Cara Therapeutics in the first quarter worth approximately $256,000. Bank of New York Mellon Corp grew its stake in Cara Therapeutics by 0.7% during the first quarter. Bank of New York Mellon Corp now owns 439,181 shares of the biopharmaceutical company’s stock valued at $5,337,000 after acquiring an additional 3,067 shares in the last quarter. Cambridge Investment Research Advisors Inc. grew its stake in Cara Therapeutics by 14.1% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 20,132 shares of the biopharmaceutical company’s stock valued at $245,000 after acquiring an additional 2,482 shares in the last quarter. Citigroup Inc. grew its stake in Cara Therapeutics by 5.7% during the first quarter. Citigroup Inc. now owns 86,370 shares of the biopharmaceutical company’s stock valued at $1,049,000 after acquiring an additional 4,654 shares in the last quarter. Finally, Natixis Advisors L.P. grew its stake in Cara Therapeutics by 101.2% during the first quarter. Natixis Advisors L.P. now owns 37,972 shares of the biopharmaceutical company’s stock valued at $461,000 after acquiring an additional 19,102 shares in the last quarter. 44.66% of the stock is currently owned by institutional investors.

About Cara Therapeutics

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.